Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (<i>RET</i>) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK)...

Full description

Bibliographic Details
Main Authors: Kit Wun Kathy Cheung, Yang Tang, Doreen Anders, Teresa Barata, Astrid Scalori, Priya Agarwal, Rucha Sane, Sravanthi Cheeti
Format: Article
Language:English
Published: MDPI AG 2024-04-01
Series:Pharmaceutics
Subjects:
hepatic impairment
pralsetinib
pharmacokinetics
Online Access:https://www.mdpi.com/1999-4923/16/4/564

Internet

https://www.mdpi.com/1999-4923/16/4/564

Similar Items